<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03645109</url>
  </required_header>
  <id_info>
    <org_study_id>0240/18HCJIM/18</org_study_id>
    <nct_id>NCT03645109</nct_id>
  </id_info>
  <brief_title>Effect of Suplementation of Vitamin D in Gestational Diabetes Mellitus</brief_title>
  <official_title>Effect of Suplementation of 5,000 UI Vitamin D3 on the Glycemic Profile in Patients With Gestational Diabetes Mellitus of the Hospital Civil de Guadalajara Dr. Juan I. Menchaca</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eva Elizabet Camarena Pulido</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Civil Juan I. Menchaca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized double-blind placebo-controlled clinical trial. Consists of the administration of
      5,000 IU of vitamin D3 vs Placebo in patients with gestational diabetes mellitus during eight
      weeks. The objective is to analyze the effects of the intervention on the biochemical
      parameters that are part of the glycemic profile (insuline, HBA1c, glucose)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two groups of patients diagnosed with gestational diabetes mellitus. Once the selection
      criteria are verified, they will be assigned randomly in one of the two arms,one of them will
      recive 5,000 IU of vitamin D and the other one placebo (talcum food grade). Baseline
      measurements of vitamin D, glucose,insulin, HBA1c, calcium, phosphorus. At the end of the
      eight weeks will be determined again the aforementioned biochemical parameters.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">December 20, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 29, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel design, two arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>The capsules with vitamin D or placebo have the same organoleptic characteristics. The jars and envelopes that contain them are identical. The envelopes are identified by a code that only knows who will analyze the data</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the parameters that make up the glycemic profile</measure>
    <time_frame>Eight weeks</time_frame>
    <description>Glucose, HBA1c, insuline,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in calcium, phosphorus and vitamin D3</measure>
    <time_frame>Eight weeks</time_frame>
    <description>Concentrations of calcium and phosphorus in blood and urine and vitamin D in blood</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Vitamin D3</condition>
  <condition>Gestational Diabetes Mellitus in Pregnancy</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive capsules with 5,000 IU of vitamin D3, one capsule orally once a day for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Will receive capsules with placebo (talcum food grade) one capsule orally once a day for eight weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Capsules with 5,000 IU of vitamin D3 once a day (one capsule)</description>
    <arm_group_label>Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Capsules with placebo (talcum food grade)</intervention_name>
    <description>Capsules with placebo (talcum food grade)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients with a single pregnancy.

          -  Patients diagnosed with GDM, which were diagnosed by a glucose tolerance curve 100
             grams of glucose, with two altered results from the following: fasting&gt; 95 miligrams /
             deciliter, 1 hour&gt; 180miligrams / deciliter, 2 hour&gt; 155miligrams / deciliter, 3hous&gt;
             140 miligrams / deciliter.

          -  Gestational age between 24 -30 weeks confirmed with ultrasound of the 1st or 2nd
             trimester

          -  Age between 18 and 40 years.

        Exclusion Criteria: Patients with pre-existing diabetes mellitus

          -  Patients with predictive factors for vitamin D hypovitaminosis such as: use of
             anticonvulsants, renal disease, glomerular filtration rate &lt;60milliliters / minute,
             thyroid disease or any other pre-existing endocrinological disorders.

          -  Hypercalciuria&gt; 300 miligrams / day

          -  Patients taking vitamin D supplementation during the 6 months prior to the study (does
             not include polyvitamins with lower vitamin D concentrations &lt;500 IU)

          -  Active and passive smoking patients.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvador Mora</last_name>
    <role>Principal Investigator</role>
    <affiliation>OPD Hospital Civil de Guadalajara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Camarena, PhMd</last_name>
    <phone>+5239424400</phone>
    <phone_ext>52324</phone_ext>
    <email>eecamarena@hcg.gob.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jorge Gonzalez, PhMd</last_name>
    <phone>+5239424400</phone>
    <phone_ext>52324</phone_ext>
    <email>glezmo@hotmail.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. J Bone Miner Res. 2011 Oct;26(10):2341-57. doi: 10.1002/jbmr.463. Erratum in: J Bone Miner Res. 2011 Dec; 26(12):3001.</citation>
    <PMID>21706518</PMID>
  </results_reference>
  <results_reference>
    <citation>Yu CK, Sykes L, Sethi M, Teoh TG, Robinson S. Vitamin D deficiency and supplementation during pregnancy. Clin Endocrinol (Oxf). 2009 May;70(5):685-90. doi: 10.1111/j.1365-2265.2008.03403.x. Epub 2008 Sep 2.</citation>
    <PMID>18771564</PMID>
  </results_reference>
  <results_reference>
    <citation>Parildar H, Dogruk Unal A, Aksan Desteli G, Cigerli O, Guvener Demirag N. Frequency of Vitamin D deficiency in pregnant diabetics at Baskent University Hospital, Istanbul. Pak J Med Sci. 2013 Jan;29(1):15-20. doi: 10.12669/pjms.291.2896.</citation>
    <PMID>24353500</PMID>
  </results_reference>
  <results_reference>
    <citation>Yazdchi R, Gargari BP, Asghari-Jafarabadi M, Sahhaf F. Effects of vitamin D supplementation on metabolic indices and hs-CRP levels in gestational diabetes mellitus patients: a randomized, double-blinded, placebo-controlled clinical trial. Nutr Res Pract. 2016 Jun;10(3):328-35. doi: 10.4162/nrp.2016.10.3.328. Epub 2016 May 16.</citation>
    <PMID>27247730</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Civil Juan I. Menchaca</investigator_affiliation>
    <investigator_full_name>Eva Elizabet Camarena Pulido</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Pregnancy in Diabetics</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

